Skip to main content
S&P 5007,608.91+0.31%DOW52,012.00-0.16%NASDAQ26,143.61+0.62%BTC$75,503.00-1.35%ETH$2,387.65-2.65%GOLD$4,379.80+1.08%OIL$103.24-2.45%
Smart Investors Daily
RC

NYSE · RCUS

Arcus Biosciences, Inc.

Healthcare · Biotechnology

$24.32

Up+$0.25 (+1.04%)

Updated Sep 16, 2026, 8:06 AM

SID Score

5.2/10

Composite research score

Smart Money

58/100

Neutral

Market cap
2.72B
P/E ratio
-7.68
Dividend yield
0.00%
52-week range
$11.30 – $31.74
Volume
1.93M
Avg. volume
1.53M

Price performance

RCUS price history

1M range · 20 trading sessions · Daily adjusted prices

RCUS closed at $24.32 after 20 trading sessions, down 17.59% for the selected period.

Last close
$24.32
Period change
-17.59%
Period low
$24.07
Period high
$31.57
Daily close
View OHLC price history
RCUS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$23.89$24.35$23.31$24.321.93M
Sep 14, 2026$24.59$24.99$24.02$24.071.72M
Sep 11, 2026$26.50$26.58$24.315$24.594.28M
Sep 10, 2026$28.02$28.455$25.91$26.152.39M
Sep 9, 2026$28.71$29.30$28.20$28.491.83M
Sep 8, 2026$29.21$29.50$28.79$29.061.36M
Sep 4, 2026$29.64$30.10$29.40$29.66736.98K
Sep 3, 2026$29.92$30.20$29.195$30.13681.7K
Sep 2, 2026$30.17$31.47$29.32$29.851.23M
Sep 1, 2026$29.18$29.87$28.68$29.711.53M
Aug 31, 2026$28.89$29.345$28.2274$29.281.11M
Aug 28, 2026$30.13$30.435$29.06$29.211.09M
Aug 27, 2026$30.75$31.01$30.36$30.59806.06K
Aug 26, 2026$31.34$31.455$30.30$30.76685.58K
Aug 25, 2026$30.11$31.58$30.11$31.57655.7K
Aug 24, 2026$30.27$30.91$29.38$30.121.3M
Aug 21, 2026$29.89$30.56$29.74$30.341.06M
Aug 20, 2026$29.88$30.39$28.94$29.521.55M
Aug 19, 2026$30.44$31.28$30.04$30.351.82M
Aug 18, 2026$29.23$29.8625$28.94$29.51896.39K

Latest RCUS news

The latest Smart Investors Daily articles mentioning RCUS.

Stock researchCompany · Overview

RCUS research

Overview

Company profile and research snapshot.

Company profile

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$29.50
Implied upside
—
Analysts
—
RCUS recent ratings
DateFirmRatingTarget
Sep 8, 2026Truist SecuritiesBuy—
Aug 6, 2026WedbushOutperform—
Aug 6, 2026Wells FargoEqual-Weight—
Jul 20, 2026HC Wainwright & Co.Buy—
Jun 4, 2026LifeSci CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif., September 09, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 26,350 shares of the Company’s common stock at an exercise price per share of $29.06, which was t

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By